The record
Johnson & Johnson’s July 27, 2026 Form 8-K disclosed an agreement for a proposed comprehensive ovarian-talc resolution, subject to stated conditions including at least 95% participation of remaining claims, with a $5.5 billion company commitment and stated payment timing.
Claim scope
What the registrant disclosed in its Form 8-K about a proposed, conditional agreement.
What this source does not establish
This record does not establish final approval, actual claimant participation, final payment, litigation outcome, liability, causation, or any scientific conclusion. Statements in the attached press release about the merits are attributed company positions.
Source
Official Corporate Disclosure — Item 7.01, Regulation FD Disclosure